Condition: Living Donor Kidney Transplantation · Sponsor: Stanford University
This study will determine whether a preparatory regimen including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when given along with recipient regulatory T cells (Tregs) will allow for eventual discontinuation of anti-rejection drugs after living donor kidney transplantation.
This description comes directly from the study's public registry record.
Kevin Ly, BS · 650-497-6057 · kevinly@stanford.edu
Stephan Busque, MD · 650-498-6189 · sbusque@stanford.edu
Always discuss trial participation with your own doctor first.
| Stanford University | Palo Alto, California, United States | Recruiting |
| Nothwestern University | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03943238